ASEP Medical Holdings (ASEP Medical Holdings) EBITDA Margin % : -814.55% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ASEP Medical Holdings EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ASEP Medical Holdings's EBITDA for the three months ended in Mar. 2024 was $-0.45 Mil. ASEP Medical Holdings's Revenue for the three months ended in Mar. 2024 was $0.06 Mil. Therefore, ASEP Medical Holdings's EBITDA margin for the quarter that ended in Mar. 2024 was -814.55%.

ASEP Medical Holdings EBITDA Margin % Historical Data

The historical data trend for ASEP Medical Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASEP Medical Holdings EBITDA Margin % Chart

ASEP Medical Holdings Annual Data

Trend

Dec21

Dec22

Dec23

EBITDA Margin %

-37,900.00

ASEP Medical Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial								-	-	-	-9,200.00	-814.55

Competitive Comparison of ASEP Medical Holdings's EBITDA Margin %

For the Biotechnology subindustry, ASEP Medical Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASEP Medical Holdings's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ASEP Medical Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ASEP Medical Holdings's EBITDA Margin % falls into.

ASEP Medical Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ASEP Medical Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-6.064	/	0.016
	=	-37,900.00 %

ASEP Medical Holdings's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-0.448	/	0.055
	=	-814.55 %

ASEP Medical Holdings (OTCPK:SEPSF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

ASEP Medical Holdings EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ASEP Medical Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ASEP Medical Holdings (ASEP Medical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASEP Medical Holdings Inc (OTCPK:SEPSF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

JJ8:Germany ASEP:Canada

Address

730 View Street, Suite 420, Victoria, BC, CAN, V8W 3Y7

Website

https://www.asepmedical.com

ASEP Medical Holdings Inc is a biotechnology firm pursuing the commercialization of broad-spectrum peptide technology. The Company is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine and is engaged in the business of acquiring research and development assets, technology, or businesses in life sciences and medical diagnostics.